Obsidian Therapeutics
Obsidian Therapeutics, headquartered in Cambridge, MA, develops precision medicines using its proprietary cytoDRiVE® platform to harness regulated therapeutic proteins. The company is advancing its lead clinical program, cytoTIL15 cell therapy (OBX-115), for treating advanced or metastatic melanoma.
Corporate Headquarters
Obsidian Therapeutics' corporate headquarters are located at 1030 Massachusetts Ave, Cambridge, MA 02138. They also have a secondary location at 1 Patriots Park, Bedford, MA 01730. Both locations serve as key operational centers for the company.
cytoDRiVE® Platform Technology
The cytoDRiVE® platform by Obsidian Therapeutics utilizes drug-responsive domains (DRDs) to regulate protein function using FDA-approved small molecules. This platform enables rapid optimization of tunable and functional proteins, contributing to the development of precision medicines. The company has an extensive synthetic biology engineering toolkit that optimizes protein functionality in various cell types.
cytoTIL15 Cell Therapy (OBX-115)
The lead clinical program, cytoTIL15 cell therapy (OBX-115), is designed to treat advanced or metastatic melanoma. This engineered TIL product, armed with membrane-bound IL15, eliminates the need for concomitant IL2 therapy, which is typically toxic and costly. OBX-115 is being investigated in clinical trials and aims to drive improved efficacy and deliver transformative outcomes for patients suffering from solid tumor malignancies.
Partnerships with Bristol Myers Squibb and Vertex Pharmaceuticals
Obsidian Therapeutics has secured partnerships with Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals to leverage the cytoDRiVE® platform technology. These collaborations aim to optimize and advance therapeutic development, combining expertise and resources to engineer precision medicines.
Development Pipeline and Future Plans
Obsidian Therapeutics is developing a novel pipeline of therapeutics, with its first TIL candidate progressing into patient trials in 2022. The company continuously expands its library of internally discovered DRDs and is open to exploring opportunistic partnerships to further its platform technology. These efforts underscore the company's commitment to pioneering engineered TIL therapies for treating solid tumor malignancies.